Can Olaparib treat prostate cancer?

Olaparib is indicated as a single agent for the treatment of adult patients with proven or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer who have progressed after prior treatment with enzalutamide or abiraterone. Before starting treatment, an FDA-approved companion diagnostic test is required to confirm the presence of specific biomarkers.

In a study of387 men with metastatic castration-resistant prostate cancer whose cancer worsened while receiving another cancer drug, olaparib itself was effective Patients with pan>BRCA1 or BRCA2 mutations were effective: Patients with these mutations and treated with olaparib lived an average of 9.8 months without their disease worsening. In a study of 796 men with metastatic and castration-resistant prostate cancer, olaparib combined with abiraterone and prednisone or prednisolone (hormone therapy) increased the time patients lived without disease progression: Patients who received olaparib and hormone therapy lived an average of 24.8 months.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.